

Anna K Langenbruch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4139794/publications.pdf>

Version: 2024-02-01

28
papers

693
citations

516710

16
h-index

580821

25
g-index

30
all docs

30
docs citations

30
times ranked

666
citing authors

#	ARTICLE	IF	CITATIONS
1	Measuring patient-relevant benefits in the treatment of psoriasis with the Patient Benefit Index: development and preliminary validation of a 10-item short form. <i>British Journal of Dermatology</i> , 2022, 187, 588-589.	1.5	3
2	Determinants of costs and benefits in atopic dermatitis routine care in Germany. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1450-1455.	2.4	3
3	Development and Validation Features of the Patient Benefit Index for the Treatment of Allergic Rhinoconjunctivitis with Allergen Immunotherapy. <i>Journal of Asthma and Allergy</i> , 2022, Volume 15, 611-621.	3.4	0
4	Determinants of costs and benefits in psoriasis routine care: results from a cross-sectional nationwide study in Germany. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e63-e65.	2.4	6
5	Quality of psoriasis care in Germany – results from the nationwide health care studies PsoHealth 2004–2017. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1536-1542.	2.4	18
6	Cost-of-illness of atopic dermatitis in Germany: data from dermatology routine care. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1346-1356.	2.4	19
7	Characterizing treatment-related patient needs in atopic eczema: insights for personalized goal orientation. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 142-152.	2.4	34
8	Disease burden and patient needs and benefits in anogenital psoriasis: developmental specificities for person-centred healthcare of emerging adults and adults. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1010-1018.	2.4	9
9	Disease burden and treatment needs of patients with psoriasis in sexually-sensitive and visible body areas: results from a large-scale survey in routine care. <i>European Journal of Dermatology</i> , 2020, 30, 267-278.	0.6	10
10	Sex-related impairment and patient needs/benefits in anogenital psoriasis: Difficult-to-communicate topics and their impact on patient-centred care. <i>PLoS ONE</i> , 2020, 15, e0235091.	2.5	17
11	Time to revise the Dermatology Life Quality Index scoring in psoriasis treatment guidelines. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e267-e269.	2.4	19
12	Does the Dermatology Life Quality Index (DLQI) underestimate the disease-specific burden of psoriasis patients?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 123-127.	2.4	32
13	Topology of psoriasis in routine care: results from high-resolution analysis of 2009 patients. <i>British Journal of Dermatology</i> , 2019, 181, 358-365.	1.5	42
14	Cost-of-illness of psoriasis – results of a German cross-sectional study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 174-180.	2.4	30
15	Benefits of a membership in a psoriasis patient organisation: a quasi-experimental longitudinal study. <i>Archives of Dermatological Research</i> , 2018, 310, 807-813.	1.9	4
16	Definition of psoriasis severity in routine clinical care: current guidelines fail to capture the complexity of long-term psoriasis management. <i>British Journal of Dermatology</i> , 2018, 179, 1385-1391.	1.5	25
17	Measurement of healthcare quality in atopic dermatitis – development and application of a set of quality indicators. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 2237-2243.	2.4	14
18	Clinical course, treatment modalities, and quality of life in patients with congenital melanocytic nevi – data from the German CMN registry. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 159-167.	0.8	24

#	ARTICLE	IF	CITATIONS
19	Quality of psoriasis care in Germany: results of the national health care study "PsoHealth". Archives of Dermatological Research, 2016, 308, 401-408.	1.9	41
20	The German National Program on Psoriasis Health Care 2005-2015: results and experiences. Archives of Dermatological Research, 2016, 308, 389-400.	1.9	47
21	Patient benefits in the treatment of psoriasis: long-term outcomes in German routine care 2007-2014. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1829-1833.	2.4	9
22	Quality of health care of atopic eczema in Germany: results of the national health care study AtopicHealth. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 719-726.	2.4	45
23	Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis. British Journal of Dermatology, 2014, 171, 1123-1128.	1.5	120
24	Quality of life measurement in chronic wounds and inflammatory skin diseases: Definitions, standards and instruments. Wound Medicine, 2014, 5, 29-38.	2.7	16
25	Therapeutic Benefits in Atopic Dermatitis Care from the Patients' Perspective: Results of the German National Health Care Study "Atopic Health". Dermatology, 2014, 228, 350-359.	2.1	20
26	Quality of Life Measures for Dermatology: Definition, Evaluation, and Interpretation. Current Dermatology Reports, 2012, 1, 148-159.	2.1	27
27	Quality of psoriasis care from the patients' perspective - results of the national health care study PsoReal. European Journal of Dermatology, 2012, 22, 518-524.	0.6	18
28	Nail psoriasis as a severity indicator: results from the PsoReal study. Patient Related Outcome Measures, 2011, 2, 1.	1.2	38